ALIVUS Q4 FY26 Results & Earnings Analysis
Sentiment: Good (Confidence: high)
Earnings Summary
Alivus Life Sciences delivered a strong FY26 with revenue growth of 6.9% YoY and record EBITDA margin of 33.6%, driven by a shift towards higher-margin non-GPL business, operational efficiencies, and CDMO recovery. The company is investing significantly in capacity (Solapur, brownfield) and R&D (high-potent API, flow chemistry) to sustain growth. Despite geopolitical headwinds, management maintains a confident outlook with EBITDA margin guidance of 30-32% for FY27. Key risks include raw material inflation, supply chain disruptions, and successful execution of backward integration and new CDMO contracts. The balance sheet remains strong with INR782 crores in cash, funding a planned INR540 crores capex in FY27.
Management Tone
- Prepared Remarks: Good — Management presented a confident narrative of transformative performance over the past two years, emphasizing record margins, strong cash generation, and a diversified portfolio. The tone was optimistic about future growth and margin sustainability.
- Q&A Session: Neutral — While management addressed questions directly, there were cautious tones regarding geopolitical uncertainties, cost inflation, and the timing of new CDMO contracts. Some answers lacked quantification, leading to a more measured sentiment.
Revenue Growth Drivers
- Non-GPL segment growth (13% YoY) driven by strong execution across regulated markets
- Recovery and ramp-up of CDMO business
- New product launches (11 new molecules) and customer additions (49 new customers)
Growth vs Margin Focus
Management explicitly stated that maintaining a high-quality business and good margin profile is a much bigger priority, and growth will not be pursued at the cost of margins.
About Alivus Life Sciences Limited
Alivus Life Sciences Limited (ALIVUS) is listed on NSE. View the latest earnings analysis, AI-powered insights, and sentiment data on StockMirror.